We advised Roche on the Rule 144A / Regulation S offering comprising four tranches of notes

Davis Polk advised Roche Holdings, Inc. in connection with its Rule 144A / Regulation S offering of $875 million aggregate principal amount of 4.790% notes due 2029, $750 million aggregate principal amount of 4.909% notes due 2031, $1.25 billion aggregate principal amount of 4.985% notes due 2034 and $1 billion aggregate principal amount of 5.218% notes due 2054, guaranteed by Roche Holding Ltd. 

Headquartered in Basel, Switzerland, the Roche Group is a leading international research-based healthcare group with two operational divisions: pharmaceuticals and diagnostics. These divisions offer products for screening and early detection, prevention, diagnosis of disease, treatment and treatment monitoring. The Roche Group operates in more than 150 countries and employs more than 100,000 people worldwide.

The Davis Polk corporate team included partner Leo Borchardt and associates Tanu Sinha and Majd Atalla. Counsel Alon Gurfinkel and associate Ya Sheng Lin provided tax advice. All members of the Davis Polk team are based in the London office. 

Copy link to share post